Beurs.nl
Uitgebreid zoeken
monitor iconMarkt Monitor
  • AEX -8,66 898,80 -0,95%
  • DE40 0,00 22.461,52 0,00%
  • US500^ +58,70 5.615,65 +1,06%
  • US30^ +576,00 42.005,80 +1,39%
  • EUR/USD +0,00 1,0819 +0,02%
  • WTI +2,44 71,42 +3,54%
  • Gold spot +38,22 3.123,52 +1,24%

Crucell Terug naar discussie overzicht

RT - Donderdag 4 Augustus

29 Posts
Pagina: 1 2 »» | Laatste | Omlaag ↓
  1. [verwijderd] 4 augustus 2005 07:23

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Slotkoers AMS: € 18.45 (dwz + 2.1 %)
    Omzet: 323 k (= vrij hoog)

    Slotkoers CRXL Nasdaq: $ 22.97 (dwz + 3.8 %)
    Omzet CRXL: 145 k

    Euro/ $= 1.233

    De Crucell koers is weer mooi uit de consolidatie om de € 18.0 gebroken.
    Chart CRXL: tinyurl.com/d5rxl
    Opvallend was de vrij hoge omzet in laatste 30 minuten op Nasdaq.
    Openingskoers staat nu voor: 18.50, maar dat zegt niet veel op dit uur.

    Hit 'em hard !
  2. [verwijderd] 4 augustus 2005 07:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hierbij 2 nuttige postings van poster UncleBake op Yahoo:
    _____________________________________________________________________
    Some newsletter comments
    by: unclebake
    Long-Term Sentiment: Strong Buy 08/03/05 07:32 pm
    Msg: 17864 of 17872

    Prohost,IMO is among the best on the web. There is a lot of free material at their site (prohostonline.) in addition to subscriber only info. This from 7/15. unclebake

    CRUCELL (CRXL) AGAIN
    As Affymetrix' (AFFX) GeneChip has become a necessity for drug discovery, Crucell's (CRXL) PER.C6(R) cell line is on its way to become the bread and butter of manufacturing and it will pay. The number of new comers who are ready to pay upfront fees and other fees and royalties is increasing, validating the firm's cell line and adding to its revenues. In the news, the new comer this time is Symphogen A/S, which will evaluate and use the PER.C6(R) cell line for production of its proprietary recombinant polyclonal antibodies, known as
    symphobodies. Symphogen will evaluate the PER.C6(R) cell line for use with Sympress™, its proprietary expression platform, for consistent manufacturing of its symphobody compositions. Symphogen will pay a signing fee and annual maintenance fees. Further financial details are not disclosed.

    Why Crucell cell line?

    Dr John Haurum, Chief Scientific Officer at Symphogen, said: "We have chosen to test the PER.C6(R) cell line based on reports of its high expression yields. Our existing expression system is producing commercially
    viable yields but we are always looking for ways to improve production efficiency.''

    The answer is clear. Crucell's technologies are on their way to becoming indispensable for the biotech industry.
    __________________________________________________________
    Recommend this Post - This post has 8 recommendations
    Another one
    by: unclebake
    Long-Term Sentiment: Strong Buy 08/03/05 07:53 pm
    Msg: 17866 of 17873

    This from changewage biotech. a new service.ub.

    BUSINESS MODEL:
    1) It uses its own technology to create vaccines
    2) It licenses its core development and manufacturing technology to other companies, which use it to identify, isolate and manufacture antibodies for vaccines and other treatments.
    They are the enabling-technology supplier to more than 30 companies, The play on Crucell is not a bet on one vaccine, one disease or even one government program -- it's banking on the growth of the entire industry segment and the evolution of cell-line manufacturing.

    CELL-LINE TECHNOLOGY: Crucell is now THE cell-line technology company and with complete and patented control of a new de facto standard for manufacturing vaccines in replicated human cells rather than in chicken eggs.
    PER.C6 is at the core of this cell-line technology and manufacturing system.
    PER.C6 was developed by inserting a fragment of the genetic code of adenovirus into a healthy human retina enabling the cell to grow indefinitely -- a very efficient and powerful assembly line. It is also used to produce genetic libraries -- the company has a 20% interest in a contract-genomics development company that uses this technology to study gene functions.
    Another proprietary Crucell technology is called AdVac and is used in combination with PER.C6 to develop highly specialized recombinant (weakened viruses or bacteria into which harmless genetic material and other disease-causing organisms are inserted) vaccines for diseases such as Ebola, West Nile virus and malaria.
    A third technology platform, MAbstract, is used in the discovery of drug targets and the identification of human antibodies that can be used to treat these targets. Crucell maintains volumes of information, targets and antibodies for use in its own and others' drug discovery efforts.
    I've presented a lot of detail, to demonstrate just how advanced the company, and its core patented technology, is at this time. This isn't something coming about at some time in the future -- it's happening now.
    PRODUCT PIPLINE: Crucell is developing its own family of vaccines against influenza, Ebola, malaria and West Nile virus. The Closest to generating sales revenue is a flu vaccine being developed with Sanofi Pasteur.
    PARTNERS: I flat-out love the Crucell business model, to share risk and generate development revenues with partners -- while retaining full technology rights.
    In the past two years, CRXL has partnered with Aventis Pasteur to develop flu vaccines, with NIH to develop an Ebola vaccine, with Merck to develop an HIV vaccine, and with GlaxoSmithKline, NYU and Walter Reed Army Institute to develop a vaccine for malaria.

    LONGER TERM: Growth should continue for a long time. The company has no real competition in its core technology business and limited competition from its own licensees in its finished vaccine business.
    It is not a trader's stock -- it's an investment in a great company with dominant, proprietary technology in an exploding market. So put away concerns about volatility and the short-term run-up -- this is a long-term play.

    WHY NOW: Government spending is increasing, the Bush and G8 initiatives are in the bag, and Crucell keeps adding partners. As I wrote "the stock may have run but the time to get in is now -- before it runs more."
    HOW AND WHEN TO BUY: Buy under $26 with a target price of $50 and be prepared to see $30, and then $35, sometime this year. There will be major bumps along the way given how much the stock has appreciated in the past two years, but these are bumps in the stock, not the company fundamentals.
    If there's a better play, I don't know it. Buy wisely, buy soon and get ready for the ride of your life!
  5. [verwijderd] 4 augustus 2005 08:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Don't be afraid to say Negentien! €19 is easy, and €20+ is inevitable! The monkeys are busy practising "Twintig!" We will soon say it so well that the price will never slip back again!

    Don't sell your CRXL for cheap to bashers!

    Go Crucell!!!

    Trudy de Aap
  6. [verwijderd] 4 augustus 2005 09:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Zet die twee berichten even in een apart draadje, zijn het wel waard om apart gezien te worden. De reeds verkregen aanbevelingen hevelen we wel over.

    Jay
  7. [verwijderd] 4 augustus 2005 09:16

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hi Jay
    Tja, er staan nu al 12 aanbevelingen. Om nu nog nieuw draadje te beginnen lijkt me te laat.
    Anyway met die aanbevelingen komt het toch mooi zichtbaar.

    Groet
  10. [verwijderd] 4 augustus 2005 10:17

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Not even 19, you are very conservative over there, you don't let the best stock in the history of the Netherlands rally too frequently.

    Oh well, not bad to be conservative. It would be fine with this monkey if CRXL went up a penny a day, it can go as slow as it likes. But the great thing is to see their steady progress in facing infectious disease with more energy than any other biotech.

    Oh well, Trudy will sleep and dream of future rallies. One day Negentien will seem very inexpensive!

    Go Crucell!!!

    Trudy de Aap
  13. [verwijderd] 4 augustus 2005 11:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    you dont read my mind Trudy...otherwise you would know HOW progressive I were and you would'nt dare to repeat your words.....far over my previous taxation...my goal...ohlala....big big quote..!!
    gr
    j.

    quote:

    trudydeaap schreef:

    Not even 19, you are very conservative over there, you don't let the best stock in the history of the Netherlands rally too frequently.

    Oh well, not bad to be conservative. It would be fine with this monkey if CRXL went up a penny a day, it can go as slow as it likes. But the great thing is to see their steady progress in facing infectious disease with more energy than any other biotech.

    Oh well, Trudy will sleep and dream of future rallies. One day Negentien will seem very inexpensive!

    Go Crucell!!!

    Trudy de Aap
  14. [verwijderd] 4 augustus 2005 11:35

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    and yes Trudy..€€ 19.00 would be better..more even..crucial for crucell..

    quote:

    janh1 schreef:

    ....en een High van €€ 18.87..! goed begin..!

    geweldige posting overigens XZorro!!
  19. [verwijderd] 4 augustus 2005 13:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik vind het even al prima als Crucell..€€ 19.00 gaat noteren! Moet zo maar kunnen!...

    Mijn uiteindelijk koersdoel schrijf ik met 3 cijfers voor de komma!

    Op Nasdaq op dit moment tot $$ 28.88 (!) slechts 2.4k in de Laat..'t is nog vroeg daar..dat wel!)

    quote:

    plumeau schreef:

    and the next move is? volgens jou?
29 Posts
Pagina: 1 2 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.213
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.865
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.846
Aedifica 3 926
Aegon 3.258 323.086
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.301
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 423
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.953
AMG 971 134.442
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.999
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.304
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.958
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449